Enxiao Li

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen et al. · The Lancet Oncology · 2020 · 584 citations

Medicine, Oncology, Pharmacology +14

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Jianming Xu, Yuxian Bai, Nong Xu et al. · Clinical Cancer Research · 2020 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

Xi Wang, Chengsheng Zhang, Xuyuan Dong et al. · World Journal of Gastrointestinal Oncology · 2022 · 47 citations · Full text

Medicine, Molecular Biology, Oncology +14

Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways

Yuan Hu, Jiayu Jing, Yu Shi et al. · Translational Cancer Research · 2021 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Ying–Hong Shi, Guohong Han, Jian Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2025 · 39 citations

Medicine, Oncology, Pharmacology +10